Tracing the voyage of SELDI-TOF MS in cancer biomarker discovery and its current depreciation trend – need for resurrection?

Surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF MS) has been established as a powerful analytical tool for biomarker discovery in oncology. This review visits the milestones achieved by this technique and scans the advantages and limitation of the technique as well. The need for expanding this technique for biomarker discovery with respect to diseases other than cancer has been emphasized. The future of this technique and its application to clinical research has been highlighted to have hit a dead-end. This review is an eye opener to break the silence, amidst the analytical chemists for revival of this technique, breaking barriers in its application to clinical research.

[1]  Jiekai Yu,et al.  Diagnosis of Pancreatic Adenocarcinoma Using Protein Chip Technology , 2008, Pancreatology.

[2]  Terence C W Poon,et al.  Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices , 2007, Expert review of proteomics.

[3]  Xun Qu,et al.  Biomarker discovery for ovarian cancer using SELDI-TOF-MS. , 2006, Gynecologic oncology.

[4]  Timothy D. Veenstra,et al.  Proteomic patterns: their potential for disease diagnosis , 2005, Molecular and Cellular Endocrinology.

[5]  Y. Miyagi,et al.  Targeted serum glycoproteomics for the discovery of lung cancer‐associated glycosylation disorders using lectin‐coupled ProteinChip arrays , 2009, Proteomics.

[6]  E. Petricoin,et al.  Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.

[7]  E. Berns,et al.  Serum proteomic patterns for ovarian cancer monitoring , 2007, International Journal of Gynecologic Cancer.

[8]  Thomas P Conrads,et al.  The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. , 2002, Biochemical and biophysical research communications.

[9]  P. Schellhammer,et al.  Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. , 2001, Cancer research.

[10]  P. Trerotoli,et al.  Body Mass Index and Serum Proteomic Profile in Breast Cancer and Healthy Women: A Prospective Study , 2012, PloS one.

[11]  William E Grizzle,et al.  Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  G. Wright,et al.  Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures , 1999, Prostate Cancer and Prostatic Diseases.

[13]  S. Gammeltoft,et al.  Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study , 2005, BMC Cancer.

[14]  E. Fung,et al.  Proteomic approaches to tumor marker discovery. , 2002, Archives of pathology & laboratory medicine.

[15]  Jing Wang,et al.  Reproducible Cancer Biomarker Discovery in SELDI-TOF MS Using Different Pre-Processing Algorithms , 2011, PloS one.

[16]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[17]  N. Zengi̇n,et al.  Importance of serum SELDI-TOF-MS analysis in the diagnosis of early lung cancer. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[18]  A. Vlahou,et al.  Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells. , 2005, Oncology reports.

[19]  Richard M Weinshilboum,et al.  Pharmacogenomics and reducing the frequency of adverse drug events. , 2003, Pharmacogenomics.

[20]  Kai Chen,et al.  Ovarian cancer classification based on dimensionality reduction for SELDI-TOF data , 2010, BMC Bioinformatics.

[21]  George L. Wright,et al.  SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. , 2002, Expert review of molecular diagnostics.

[22]  T. Yip,et al.  New desorption strategies for the mass spectrometric analysis of macromolecules , 1993 .

[23]  C. Ahlin,et al.  A study of serum biomarkers associated with relapse of cervical cancer. , 2012, Anticancer research.

[24]  Clara S. M. Tang,et al.  Adaptive Evolution Hotspots at the GC-Extremes of the Human Genome: Evidence for Two Functionally Distinct Pathways of Positive Selection , 2010, Adv. Bioinformatics.

[25]  D. Hochstrasser,et al.  A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.

[26]  G. Wright,et al.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.

[27]  K. Mechtler,et al.  Automated, on‐line two‐dimensional nano liquid chromatography tandem mass spectrometry for rapid analysis of complex protein digests , 2004, Proteomics.

[28]  Peter Albers,et al.  Analysis of microdissected prostate tissue with ProteinChip arrays--a way to new insights into carcinogenesis and to diagnostic tools. , 2002, International journal of molecular medicine.

[29]  Jean-Paul Chapelle,et al.  Challenges for Biomarker Discovery in Body Fluids Using SELDI-TOF-MS , 2009, Journal of biomedicine & biotechnology.

[30]  L C Whelan,et al.  Applications of SELDI-MS technology in oncology , 2008, Journal of cellular and molecular medicine.

[31]  D. Hochstrasser,et al.  A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt‐Jakob disease , 2003, Proteomics.

[32]  S. Weinberger,et al.  Current developments in SELDI affinity technology. , 2004, Mass spectrometry reviews.

[33]  E. Kohn,et al.  SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. , 2005, Pharmacogenomics.

[34]  D. Chan,et al.  Characterization of Renal Allograft Rejection by Urinary Proteomic Analysis , 2003, Annals of surgery.

[35]  P. Langford,et al.  Biomarker discovery in infectious diseases using SELDI. , 2007, Future microbiology.

[36]  P R Taylor,et al.  Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. , 2000, Cancer research.

[37]  M. Deeg,et al.  Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients , 2004, Laboratory Investigation.

[38]  O John Semmes,et al.  Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  A. Görg,et al.  Current two‐dimensional electrophoresis technology for proteomics , 2004, Proteomics.

[40]  Jeffrey S. Morris,et al.  Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..

[41]  Rency S Varghese,et al.  Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma , 2006, Proteomics.

[42]  Fan Zhang,et al.  T3SEdb: data warehousing of virulence effectors secreted by the bacterial Type III Secretion System , 2010, BMC Bioinformatics.

[43]  E. Diamandis.  Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[44]  N. Vasudev,et al.  Proteomics and the search for biomarkers for renal cancer. , 2013, Clinical biochemistry.

[45]  T. Veenstra,et al.  Characterization of the Low Molecular Weight Human Serum Proteome*S , 2003, Molecular & Cellular Proteomics.

[46]  S. Weinberger,et al.  Recent advancements in surface‐enhanced laser desorption/ionization‐time of flight‐mass spectrometry , 2000, Electrophoresis.

[47]  E. Petricoin,et al.  Early detection: Proteomic applications for the early detection of cancer , 2003, Nature Reviews Cancer.

[48]  B. De Moor,et al.  The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles. , 2009, Anticancer research.

[49]  Thomas Deufel,et al.  Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. , 2007, Clinical chemistry and laboratory medicine.

[50]  P. Selby,et al.  Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. , 2003, Cancer research.

[51]  M. Roberts,et al.  Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical chemistry. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[52]  Rebecca E Caffrey,et al.  A review of experimental design best practices for proteomics based biomarker discovery: focus on SELDI-TOF. , 2010, Methods in molecular biology.

[53]  Marcus Schmidt,et al.  Surface-enhanced Laser Desorption/Ionisation Time-of-flight Mass Spectrometry to Detect Breast Cancer Markers in Tears and Serum. , 2009, Cancer genomics & proteomics.

[54]  M. Herbster,et al.  Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum , 2006, The Lancet.

[55]  M. Kostrzewa,et al.  Mass spectrometry-based clinical proteomics. , 2003, Pharmacogenomics.

[56]  T. Yip,et al.  Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology , 2009, Acta obstetricia et gynecologica Scandinavica.

[57]  K. Strimbu,et al.  What are biomarkers? , 2010, Current opinion in HIV and AIDS.

[58]  Kym Faull,et al.  Characterization of serum biomarkers for detection of early stage ovarian cancer , 2005, Proteomics.

[59]  R. Berkowitz,et al.  Proteomic-Based Discovery and Characterization of Glycosylated Eosinophil-Derived Neurotoxin and COOH-Terminal Osteopontin Fragments for Ovarian Cancer in Urine , 2006, Clinical Cancer Research.

[60]  F. Bertucci,et al.  Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery. , 2008, Future oncology.

[61]  E. Fung,et al.  ProteinChip clinical proteomics: computational challenges and solutions. , 2002, BioTechniques.

[62]  R. Mayeux.  Biomarkers: Potential uses and limitations , 2004, NeuroRX.

[63]  Uwe Claussen,et al.  Mass spectrometry meets chip technology: A new proteomic tool in cancer research? , 2001, Electrophoresis.

[64]  S Hanash,et al.  Proteomics in early detection of cancer. , 2001, Clinical chemistry.

[65]  Thomas P Conrads,et al.  SELDI-TOF MS for diagnostic proteomics. , 2003, Analytical chemistry.

[66]  M. Ferrari,et al.  Clinical proteomics: Written in blood , 2003, Nature.

[67]  S. Gygi,et al.  Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry , 2003 .

[68]  Pierre Bedossa,et al.  Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases , 2005, Hepatology.

[69]  Kendall Powell.  Proteomics delivers on promise of cancer biomarkers , 2003, Nature Medicine.